Evaluating the efficacy and safety of continuous arterial infusion chemotherapy with cisplatin and 5-fluorouracil in treating oral cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      Objective: To investigate the clinical effects and safety for cisplatin combined with 5-fluorouracil (5-FU) intra-arterial chemotherapy in the treatment of oral cancer.Materials and Methods: A total of ninety cases with oral cancer were recruited in this study. Forty-three subjects received the pingyangmycin (PYM) (control group) with PYM 8 mg, intramuscular injection, QD for 21 days per cycle. Moreover, other 47 cases received cisplatin 100 mg/m 2 24 h perfusion chemotherapy, day 1 with 21 days per cycle, and 5-FU 1000 mg/m 2 perfusion chemotherapy 72 h with 21 days per cycle. All the patients received three cycles treatment. After three cycles chemotherapy, the objective response rate (ORR) and chemotherapy-related toxicities were evaluated between the two groups.Results: The ORR were 53.49% and 72.34%, respectively in the control and observation group which indicated observation group significant higher (P < 0.05). The chemotherapy-related toxicities incidence was much higher in control group compared with observation group (36.17% vs. 11.63%, P < 0.05).Conclusion: Cisplatin combined with 5-FU intra-arterial chemotherapy was effective in the treatment of oral cancer with less toxicties. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Journal of Cancer Research & Therapeutics is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)